Antiviral drug resistance increases hepatocellular carcinoma: A prospective decompensated cirrhosis cohort study

Table 3 Comparison of drug-resistant mutations between successful and failed rescue therapy n (%)

Mutations	Successful rescue therapy (n = 27)	Failed rescue therapy (n = 9)	P value
rtM204V			0.443
+	1 (3.7)	1 (11.1)
-	26 (96.3)	8 (88.9)
rtM204I			0.333
+	4 (14.8)	3 (33.3)
-	23 (85.2)	6 (66.7)
rtA181T			0.006
+	2 (7.4)	5 (55.6)
-	25 (92.6)	4 (44.4)
rtL180M			0.255
+	2 (7.4)	2 (22.2)
-	25 (92.6)	7 (77.8)
rtL80I			0.057
+	0 (0)	2 (22.2)
-	27 (100)	7 (77.8)
rtN236T			0.057
+	0 (0)	2 (22.2)
-	27 (100)	7 (77.8)
rtT184I			0.250
+	0 (0)	1 (11.1)
-	27 (100)	8 (88.9)
rtS202G			1.000
+	1 (3.7)	0 (0)
-	26 (96.3)	9 (100)
rtA181T + rtM204I			0.443
+	1 (3.7)	1 (11.1)
-	26 (96.3)	8 (88.9)
rtA181T + rtL180M			1.000
+	1 (3.7)	0 (0)
-	26 (96.3)	9 (100)
rtM204V + rtL180M			1.000
+	1 (3.7)	0 (0)
-	26 (96.3)	9 (100)
rtA181T + rtN236T			0.057
+	0 (0)	2 (22.2)
-	27 (100)	7 (77.8)
rtA181T + rtL80I			0.250
+	0 (0)	1 (11.1)
-	27 (100)	8 (88.9)
rtA181T + rtM204I + rtT184I			0.250
+	0 (0)	1 (11.1)
-	27 (100)	8 (88.9)
rtM204I + rtL180M + rtL80I			0.250
+	0 (0)	1 (11.1)
-	27 (100)	8 (88.9)

+: DR mutations positive; -: DR mutations negative; DR: Drug resistance.